This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (239)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Endocrine Diseases  • Diabetes Mellitus  • Articles for Residents  • Macular Disorders  • Alert me on articles by topic

Jost B. Jonas, MD; Ingrid Kreissig, MD; Antje Söfker, MD; Robert F. Degenring, MD

Arch Ophthalmol. 2003;121:57-61.

Objective  To evaluate the clinical outcome of an intravitreal injection of triamcinolone acetonide as treatment of diffuse diabetic macular edema.

Participants  This prospective, interventional, clinical case series study included 20 patients (26 eyes) who received an intravitreal injection of 25 mg of triamcinolone acetonide for treatment of diffuse diabetic macular edema. Mean ± SD follow-up time was 6.64 ± 6.10 months. The study group was compared with a control group of 16 patients who underwent macular grid laser coagulation.

Main Outcome Measures  Visual acuity and intraocular pressure.

Results  In the study group, visual acuity improved significantly (P<.001), from 0.12 ± 0.08 at baseline to a maximum of 0.19 ± 0.14 during follow-up. Seventeen (81%) of 21 eyes with a follow-up period of more than 1 month had improved visual acuity. In the control group, visual acuity did not change significantly. In the study group, intraocular pressure increased significantly (P<.001), from 16.9 ± 2.5 mm Hg to a mean maximal value of 21.3 ± 4.7 mm Hg, and decreased significantly (P = .03) to 17.7 ± 4.7 mm Hg at the study's end.

Conclusion  Intravitreal injection of 25 mg of triamcinolone acetonide may be beneficial for improving visual acuity in patients with clinically significant diffuse diabetic macular edema.

From the Department of Ophthalmology and the Eye Hospital, Faculty for Clinical Medicine–Mannheim, Ruprecht Karls University, Heidelberg, Germany. The authors have no proprietary interest in the products or companies mentioned in this article.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Increased incidence of sterile endophthalmitis following intravitreal preserved triamcinolone acetonide
Jonisch et al.
Br. J. Ophthalmol. 2008;92:1051-1054.
ABSTRACT | FULL TEXT  

Intravitreal triamcinolone versus laser photocoagulation for persistent diabetic macular oedema
Ockrim et al.
Br. J. Ophthalmol. 2008;92:795-799.
ABSTRACT | FULL TEXT  

Comparison of 4 mg versus 20 mg intravitreal triamcinolone acetonide injections
Tammewar et al.
Br. J. Ophthalmol. 2008;92:810-813.
ABSTRACT | FULL TEXT  

Gene Expression Profiles of Human Trabecular Meshwork Cells Induced by Triamcinolone and Dexamethasone
Fan et al.
IOVS 2008;49:1886-1897.
ABSTRACT | FULL TEXT  

Effect of Posterior Sub-Tenon Administration of Triamcinolone Acetonide on Leukocyte Dynamics in Rat Retinal Microcirculation after Panretinal Photocoagulation
Mizuno et al.
IOVS 2008;49:2127-2133.
ABSTRACT | FULL TEXT  

Intravitreal Triamcinolone Acetonide Inhibits Breakdown of the Blood-Retinal Barrier Through Differential Regulation of VEGF-A and Its Receptors in Early Diabetic Rat Retinas
Zhang et al.
Diabetes 2008;57:1026-1033.
ABSTRACT | FULL TEXT  

Short-term Safety and Efficacy of Intravitreal Triamcinolone Acetonide for Uveitic Macular Edema in Children
Sallam et al.
Arch Ophthalmol 2008;126:200-205.
ABSTRACT | FULL TEXT  

Trans-Tenon's retrobulbar triamcinolone acetonide injection for macular oedema related to branch retinal vein occlusion
Kawaji et al.
Br. J. Ophthalmol. 2008;92:81-83.
ABSTRACT | FULL TEXT  

Triamcinolone Acetonide-Mediated Oxidative Injury in Retinal Cell Culture: Comparison with Dexamethasone
Chung et al.
IOVS 2007;48:5742-5749.
ABSTRACT | FULL TEXT  

Management of Diabetic Retinopathy: A Systematic Review
Mohamed et al.
JAMA 2007;298:902-916.
ABSTRACT | FULL TEXT  

Effects of Periocular Administration of Triamcinolone Acetonide on Leukocyte-Endothelium Interactions in the Ischemic Retina
Mizuno et al.
IOVS 2007;48:2831-2836.
ABSTRACT | FULL TEXT  

Predictive factors for short-term visual outcome after intravitreal triamcinolone acetonide injection for diabetic macular oedema: an optical coherence tomography study
Brasil et al.
Br. J. Ophthalmol. 2007;91:761-765.
ABSTRACT | FULL TEXT  

Combined triamcinolone acetonide injection and grid laser photocoagulation: a promising treatment for diffuse diabetic macular oedema?
Iida
Br. J. Ophthalmol. 2007;91:407-408.
FULL TEXT  

Randomized Controlled Study of an Intravitreous Dexamethasone Drug Delivery System in Patients With Persistent Macular Edema
Kuppermann et al.
Arch Ophthalmol 2007;125:309-317.
ABSTRACT | FULL TEXT  

A prospective randomised trial of different doses of intravitreal triamcinolone for diabetic macular oedema
Lam et al.
Br. J. Ophthalmol. 2007;91:199-203.
ABSTRACT | FULL TEXT  

Comparison of the hypothalamic-pituitary-adrenal axis susceptibility upon single-dose i.m. depot versus long-acting i.v. triamcinolone acetonide therapy: a direct pharmacokinetic correlation.
Abraham et al.
J Endocrinol 2006;191:491-496.
ABSTRACT | FULL TEXT  

Effects of Intravitreous Injection of Preserved and Nonpreserved Triamcinolone in Rabbit Retina--Reply
Dierks et al.
Arch Ophthalmol 2006;124:1666-1668.
FULL TEXT  

Intravitreal triamcinolone for diffuse diabetic macular oedema.
Longo
Br. J. Ophthalmol. 2006;90:1079-1080.
FULL TEXT  

Intraocular pressure alterations following intravitreal triamcinolone acetonide
Rhee et al.
Br. J. Ophthalmol. 2006;90:999-1003.
ABSTRACT | FULL TEXT  

Photographic estimation of the duration of high dose intravitreal triamcinolone in the vitrectomised eye
Kosobucki et al.
Br. J. Ophthalmol. 2006;90:705-708.
ABSTRACT | FULL TEXT  

Triamcinolone as adjunctive treatment to laser panretinal photocoagulation for proliferative diabetic retinopathy.
Bandello et al.
Arch Ophthalmol 2006;124:643-650.
ABSTRACT | FULL TEXT  

Macular grid photocoagulation after intravitreal triamcinolone acetonide for diffuse diabetic macular edema.
Kang et al.
Arch Ophthalmol 2006;124:653-658.
ABSTRACT | FULL TEXT  

Sequenced combined intravitreal triamcinolone and indocyanine green angiography-guided photodynamic therapy for retinal angiomatous proliferation.
Freund et al.
Arch Ophthalmol 2006;124:487-492.
ABSTRACT | FULL TEXT  

Should corticosteroids be considered as part of the standard care with photodynamic therapy?
Zarbin
Arch Ophthalmol 2006;124:563-571.
FULL TEXT  

Toxicity of Triamcinolone Acetonide on Retinal Neurosensory and Pigment Epithelial Cells
Narayanan et al.
IOVS 2006;47:722-728.
ABSTRACT | FULL TEXT  

Electroretinographic Effects of an Intravitreal Injection of Triamcinolone in Rabbit Retina
Dierks et al.
Arch Ophthalmol 2005;123:1563-1569.
ABSTRACT | FULL TEXT  

Intravitreal Injection Versus Sub-Tenon's Infusion of Triamcinolone Acetonide for Refractory Diabetic Macular Edema: A Randomized Clinical Trial
Bonini-Filho et al.
IOVS 2005;46:3845-3849.
ABSTRACT | FULL TEXT  

Predictive Factors for Visual Acuity After Intravitreal Triamcinolone Treatment for Diabetic Macular Edema
Jonas et al.
Arch Ophthalmol 2005;123:1338-1343.
ABSTRACT | FULL TEXT  

Intravitreal triamcinolone acetonide for refractory diabetic macular oedema
Fernando and Pandit
JRSM 2005;98:421-422.
FULL TEXT  

Comparison of different techniques for purification of triamcinolone acetonide suspension for intravitreal use
Garcia-Arumi et al.
Br. J. Ophthalmol. 2005;89:1112-1114.
ABSTRACT | FULL TEXT  

Acute Endophthalmitis Incidence: Intravitreal Triamcinolone
Westfall et al.
Arch Ophthalmol 2005;123:1075-1077.
ABSTRACT | FULL TEXT  

Dosage dependency of intravitreal triamcinolone acetonide as treatment for diabetic macular oedema
Spandau et al.
Br. J. Ophthalmol. 2005;89:999-1003.
ABSTRACT | FULL TEXT  

Intravitreal triamcinolone therapy for diabetic macular oedema
Vernon
Br. J. Ophthalmol. 2005;89:931-933.
FULL TEXT  

Effect of triamcinolone acetonide on proliferation of retinal endothelial cells in vitro and in vivo
Spandau et al.
Br. J. Ophthalmol. 2005;89:745-747.
ABSTRACT | FULL TEXT  

Effect of Intravitreal Triamcinolone Acetonide on Susceptibility to Experimental Bacterial Endophthalmitis and Subsequent Response to Treatment
Bucher et al.
Arch Ophthalmol 2005;123:649-653.
ABSTRACT | FULL TEXT  

Intravitreal Injection of Corticosteroid Attenuates Leukostasis and Vascular Leakage in Experimental Diabetic Retina
Tamura et al.
IOVS 2005;46:1440-1444.
ABSTRACT | FULL TEXT  

It's Time for a Clinical Trial to Investigate Intravitreal Triamcinolone for Macular Edema Due to Retinal Vein Occlusion: The SCORE Study
Scott and Ip
Arch Ophthalmol 2005;123:581-582.
FULL TEXT  

Vascular Endothelial Growth Factor Reduced and Connective Tissue Growth Factor Induced by Triamcinolone in ARPE19 Cells under Oxidative Stress
Matsuda et al.
IOVS 2005;46:1062-1068.
ABSTRACT | FULL TEXT  

Diffuse diabetic macular oedema treated by intravitreal triamcinolone acetonide: a comparative, non-randomised study
Jonas et al.
Br. J. Ophthalmol. 2005;89:321-326.
ABSTRACT | FULL TEXT  

Regression of Sight-Threatening Macular Edema in Type 2 Diabetes Following Treatment With the Anti-Tumor Necrosis Factor Monoclonal Antibody Infliximab
Sfikakis et al.
Diabetes Care 2005;28:445-447.
FULL TEXT  

Subthreshold diode micropulse photocoagulation for the treatment of clinically significant diabetic macular oedema
Luttrull et al.
Br. J. Ophthalmol. 2005;89:74-80.
ABSTRACT | FULL TEXT  

Vitreous Levels of Vascular Endothelial Growth Factor and Stromal-Derived Factor 1 in Patients With Diabetic Retinopathy and Cystoid Macular Edema Before and After Intraocular Injection of Triamcinolone
Brooks et al.
Arch Ophthalmol 2004;122:1801-1807.
ABSTRACT | FULL TEXT  

Factors influencing visual acuity after intravitreal triamcinolone acetonide as treatment of exudative age related macular degeneration
Jonas et al.
Br. J. Ophthalmol. 2004;88:1557-1562.
ABSTRACT | FULL TEXT  

Diabetic Retinopathy
Fong et al.
Diabetes Care 2004;27:2540-2553.
FULL TEXT  

Intravitreal triamcinolone for the treatment of refractory diabetic macular oedema with hard exudates: an optical coherence tomography study
Ciardella et al.
Br. J. Ophthalmol. 2004;88:1131-1136.
ABSTRACT | FULL TEXT  

Intravitreal Triamcinolone for the Management of Macular Edema Due to Nonischemic Central Retinal Vein Occlusion
Bashshur et al.
Arch Ophthalmol 2004;122:1137-1140.
ABSTRACT | FULL TEXT  

Intravitreal Injection of Triamcinolone: An emerging treatment for diabetic macular edema
Ip
Diabetes Care 2004;27:1794-1797.
FULL TEXT  

Intravitreal Injection of Triamcinolone for Diffuse Diabetic Macular Edema
Wong et al.
Arch Ophthalmol 2004;122:1082-1082.
FULL TEXT  

Safety and Efficacy of Intravitreal Triamcinolone
Savage and Roh
Arch Ophthalmol 2004;122:1083-1083.
FULL TEXT  

Intravitreal Injection of Triamcinolone for Diffuse Macular Edema
Rodriguez-Coleman et al.
Arch Ophthalmol 2004;122:1085-1086.
FULL TEXT  

Intravitreal Injection of Triamcinolone for Diffuse Macular Edema--Reply
Jonas et al.
Arch Ophthalmol 2004;122:1086-1088.
FULL TEXT  

Intravitreal Injection of Triamcinolone Acetonide for Diabetic Macular Edema
Kuhn and Barker
Arch Ophthalmol 2004;122:1082-1083.
FULL TEXT  

Intravitreal Injection of Triamcinolone for Diffuse Diabetic Macular Edema
Chan et al.
Arch Ophthalmol 2004;122:1083-1085.
FULL TEXT  

The Toxic and Stress Responses of Cultured Human Retinal Pigment Epithelium (ARPE19) and Human Glial Cells (SVG) in the Presence of Triamcinolone
Yeung et al.
IOVS 2003;44:5293-5300.
ABSTRACT | FULL TEXT  

Intravitreal triamcinolone acetonide for exudative age related macular degeneration
Jonas et al.
Br. J. Ophthalmol. 2003;87:462-468.
ABSTRACT | FULL TEXT